MX2013010379A - Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas. - Google Patents
Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas.Info
- Publication number
- MX2013010379A MX2013010379A MX2013010379A MX2013010379A MX2013010379A MX 2013010379 A MX2013010379 A MX 2013010379A MX 2013010379 A MX2013010379 A MX 2013010379A MX 2013010379 A MX2013010379 A MX 2013010379A MX 2013010379 A MX2013010379 A MX 2013010379A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- erbb3
- patient
- hormone refractory
- refractory breast
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 7
- 208000018819 hormone-resistant breast carcinoma Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 4
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 2
- 229940102550 Estrogen receptor antagonist Drugs 0.000 abstract 2
- 239000003886 aromatase inhibitor Substances 0.000 abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 102000048238 Neuregulin-1 Human genes 0.000 abstract 1
- 108090000556 Neuregulin-1 Proteins 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000000833 heterodimer Substances 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451848P | 2011-03-11 | 2011-03-11 | |
| US201261604281P | 2012-02-28 | 2012-02-28 | |
| PCT/US2012/028792 WO2012125573A2 (en) | 2011-03-11 | 2012-03-12 | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013010379A true MX2013010379A (es) | 2014-03-27 |
Family
ID=45894680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013010379A MX2013010379A (es) | 2011-03-11 | 2012-03-12 | Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140134170A1 (OSRAM) |
| EP (1) | EP2683741A2 (OSRAM) |
| JP (1) | JP2014508782A (OSRAM) |
| KR (1) | KR20140044796A (OSRAM) |
| CN (1) | CN103562226A (OSRAM) |
| AU (1) | AU2012229147B2 (OSRAM) |
| BR (1) | BR112013022882A2 (OSRAM) |
| CA (1) | CA2828075A1 (OSRAM) |
| EA (1) | EA201300996A1 (OSRAM) |
| MX (1) | MX2013010379A (OSRAM) |
| SG (1) | SG192844A1 (OSRAM) |
| WO (1) | WO2012125573A2 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20131113T1 (hr) * | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| JP2013522237A (ja) * | 2010-03-11 | 2013-06-13 | メリマック ファーマシューティカルズ インコーポレーティッド | トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用 |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| WO2013164689A2 (en) | 2012-05-02 | 2013-11-07 | Lantto, Johan | Humanized pan-her antibody compositions |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| SG11201607109QA (en) | 2014-02-28 | 2016-09-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
| SI3110849T1 (sl) | 2014-02-28 | 2021-01-29 | Merus N.V. | Protitelo, ki veže ERBB-2 in ERBB-3 |
| CN104208069A (zh) * | 2014-05-08 | 2014-12-17 | 上海市计划生育科学研究所 | 双炔失碳酯组合物和疾病治疗方法 |
| HK1248539A1 (zh) | 2015-04-17 | 2018-10-19 | 梅里麦克制药股份有限公司 | 借助塞里班土单抗的组合治疗 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| ITUB20160828A1 (it) * | 2016-02-18 | 2017-08-18 | Univ Degli Studi Genova | Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro |
| AU2017235450A1 (en) * | 2016-03-15 | 2018-08-16 | Merrimack Pharmaceuticals, Inc. | Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody |
| BR112019007254A2 (pt) | 2016-10-11 | 2019-07-02 | Duke University | tratamento lasofoxifeno de câncer de mama er+ |
| US10624874B2 (en) | 2017-01-10 | 2020-04-21 | Zhejiang Jiachi Development Pharmaceuticals Ltd | Lasofoxifene modulation of membrane-initiated estrogen signals and methods for tumor treatment |
| CA3058343A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 and erbb-3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene |
| US12195551B2 (en) * | 2017-05-17 | 2025-01-14 | Merus N.V. | Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer |
| HUE071182T2 (hu) | 2017-08-09 | 2025-08-28 | Merus Nv | EGFR és CMET kötõ antitestek |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| WO2019199891A1 (en) | 2018-04-10 | 2019-10-17 | Duke University | Lasofoxifene treatment of breast cancer |
| CN115843256A (zh) * | 2020-10-15 | 2023-03-24 | 上海翰森生物医药科技有限公司 | 抗erbb3抗体或其抗原结合片段及其医药用途 |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP2258726A1 (en) | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US7390632B2 (en) | 1999-09-30 | 2008-06-24 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
| US7612042B2 (en) | 2001-05-31 | 2009-11-03 | Tumor Biology Investment Group, Inc. | Methods for inhibiting heregulin and treating cancer |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| CN100424175C (zh) | 2002-03-26 | 2008-10-08 | 上海泽生科技开发有限公司 | ErbB-3 用于肿瘤治疗的方法和组合物 |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| HRP20131113T1 (hr) * | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| PL2132229T3 (pl) | 2007-03-01 | 2016-12-30 | Kompozycje rekombinowanych przeciwciał anty-receptor czynnika wzrostu naskórka | |
| JP2010526797A (ja) | 2007-05-11 | 2010-08-05 | エンゾン ファーマシューティカルズ，インコーポレーテッド | Ｈｅｒ３のモジュレーションのためのｒｎａアンタゴニスト化合物 |
| MX2010011145A (es) | 2008-04-11 | 2011-04-11 | Merrimack Pharmaceuticals Inc | Enlazadores de la albumina de suero humana y conjugados de la misma. |
| BRPI0917871A2 (pt) | 2008-08-15 | 2017-06-20 | Merrimack Pharmaceuticals Inc | agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| CN102356092B (zh) | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
| US8362215B2 (en) | 2009-04-29 | 2013-01-29 | Trellis Bioscience, Llc | Antibodies immunoreactive with heregulin-coupled HER3 |
| CA2777242A1 (en) * | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
| JP2013522237A (ja) * | 2010-03-11 | 2013-06-13 | メリマック ファーマシューティカルズ インコーポレーティッド | トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用 |
| WO2011136911A2 (en) | 2010-04-09 | 2011-11-03 | Aveo Pharmaceuticals, Inc. | Anti-erbb3 antibodies |
| UY33498A (es) * | 2010-07-09 | 2013-01-03 | Sanofi Aventis | Combinaciones de inhibidores de quinasas para el tratamiento de cancer |
-
2012
- 2012-03-12 JP JP2013557943A patent/JP2014508782A/ja active Pending
- 2012-03-12 EP EP12711080.7A patent/EP2683741A2/en not_active Withdrawn
- 2012-03-12 MX MX2013010379A patent/MX2013010379A/es unknown
- 2012-03-12 SG SG2013062856A patent/SG192844A1/en unknown
- 2012-03-12 BR BR112013022882A patent/BR112013022882A2/pt not_active IP Right Cessation
- 2012-03-12 WO PCT/US2012/028792 patent/WO2012125573A2/en not_active Ceased
- 2012-03-12 EA EA201300996A patent/EA201300996A1/ru unknown
- 2012-03-12 CN CN201280012969.XA patent/CN103562226A/zh active Pending
- 2012-03-12 AU AU2012229147A patent/AU2012229147B2/en not_active Ceased
- 2012-03-12 CA CA2828075A patent/CA2828075A1/en not_active Abandoned
- 2012-03-12 US US14/004,598 patent/US20140134170A1/en not_active Abandoned
- 2012-03-12 KR KR1020137026392A patent/KR20140044796A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140044796A (ko) | 2014-04-15 |
| BR112013022882A2 (pt) | 2016-12-20 |
| SG192844A1 (en) | 2013-09-30 |
| WO2012125573A2 (en) | 2012-09-20 |
| EP2683741A2 (en) | 2014-01-15 |
| AU2012229147B2 (en) | 2015-12-24 |
| JP2014508782A (ja) | 2014-04-10 |
| AU2012229147A1 (en) | 2013-03-14 |
| EA201300996A1 (ru) | 2014-01-30 |
| NZ614427A (en) | 2015-08-28 |
| CA2828075A1 (en) | 2012-09-20 |
| WO2012125573A3 (en) | 2012-12-27 |
| CN103562226A (zh) | 2014-02-05 |
| US20140134170A1 (en) | 2014-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013010379A (es) | Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas. | |
| MX344355B (es) | Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal. | |
| PH12012502022B1 (en) | Anti-erbb3 antibodies | |
| MX2013009732A (es) | Terapias de combinacion comprendiendo agentes anti-erbb3. | |
| MX350861B (es) | Anticuerpos frente al receptor del factor de crecimiento epidérmico (egfr) y usos de éstos. | |
| CL2016002359A1 (es) | Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco | |
| EP4589014A3 (en) | Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden | |
| MX2019004193A (es) | Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer. | |
| PH12014502048B1 (en) | Treatment of cancer with tor kinase inhibitors | |
| PH12014502437A1 (en) | Anti-egfr antibodies and uses threof | |
| JO3291B1 (ar) | الأجسام المضادة لـ csf-1r | |
| PH12014502419A1 (en) | Specific binding proteins and uses thereof | |
| IN2014KN00871A (OSRAM) | ||
| JO3370B1 (ar) | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 | |
| MX358728B (es) | Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados. | |
| MX2014011500A (es) | Diagnosticos y tratamientos relacionados a inhibidores her3. | |
| MY163502A (en) | Antibodies specifically binding to the epidermal growth factor receptor | |
| MX2015005928A (es) | Metodos para tratar el cancer de ovario con antagonistas de dll4. | |
| IN2014CN04652A (OSRAM) | ||
| MX2014013763A (es) | Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer. | |
| HK1193827A (en) | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers | |
| MX2022001411A (es) | Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5. | |
| PL423203A1 (pl) | Czynnik wzrostu do zastosowania w terapii przeciwnowotworowej dla pacjentów z nowotworami, w których przynajmniej część komórek wykazuje ekspresję EGFRvIII | |
| GB201118899D0 (en) | Marker and target for responsiveness and resistance to cancer agents | |
| MY184687A (en) | Methods of inhibiting tumor growth by antagonizing il-6 receptor |